Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-17
DOI
10.1038/srep30245
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
- (2015) Valentina E. Schneeberger et al. Oncotarget
- Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin
- (2014) L Wei et al. CANCER GENE THERAPY
- Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
- (2014) Nobuaki Ochi et al. EXPERIMENTAL CELL RESEARCH
- Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment
- (2014) Manju Saraswathy et al. Materials Today
- Gold Nanoparticles for Nucleic Acid Delivery
- (2014) Ya Ding et al. MOLECULAR THERAPY
- The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism
- (2013) Victor Jeannot et al. INTERNATIONAL JOURNAL OF CANCER
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Drug for an 'undruggable' protein
- (2013) Nicole M. Baker et al. NATURE
- Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape
- (2013) Jerome Gilleron et al. NATURE BIOTECHNOLOGY
- Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
- (2012) Edita Aksamitiene et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma
- (2012) A. Hoeben et al. INTERNATIONAL JOURNAL OF CANCER
- Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer
- (2012) Xiuling Zhi et al. IUBMB LIFE
- Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
- (2012) C M Furcht et al. ONCOGENE
- Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
- (2011) H Li et al. Advances in Medical Sciences
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
- (2011) Lionel Faivre et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design
- (2011) Kevin Buyens et al. JOURNAL OF CONTROLLED RELEASE
- Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- (2011) N. Sunaga et al. MOLECULAR CANCER THERAPEUTICS
- Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition
- (2010) Xichun Liu et al. BMC CANCER
- Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations
- (2010) Matthew J. Lazzara et al. CANCER RESEARCH
- Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
- (2010) Zhenfeng Zhang et al. CARCINOGENESIS
- Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia
- (2010) Olga Bermudez et al. JOURNAL OF CELLULAR PHYSIOLOGY
- siRNA delivery systems for cancer treatment
- (2009) Yu-Kyoung Oh et al. ADVANCED DRUG DELIVERY REVIEWS
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Gene Regulation with Polyvalent siRNA−Nanoparticle Conjugates
- (2009) David A. Giljohann et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells
- (2009) Yung-Yen Chiang MOLECULAR CARCINOGENESIS
- Knocking down barriers: advances in siRNA delivery
- (2009) Kathryn A. Whitehead et al. NATURE REVIEWS DRUG DISCOVERY
- Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications
- (2008) Chuan Huang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Grb2 signaling in cell motility and cancer
- (2008) Alessio Giubellino et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis
- (2008) Peng Liu et al. FEBS LETTERS
- Stability Study of Unmodified siRNA and Relevance to Clinical Use
- (2008) Robyn P. Hickerson et al. OLIGONUCLEOTIDES
- Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway
- (2008) O Bermudez et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started